Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Lesson from Clinical Practice

Non-invasive ventilation (NIV) induced bilateral subcutaneous emphysema in SARS COV-2 patient: A rare occurrence

Sunil Routaray, Chandrakant Prasad, Vanitha Rajagopalan *

Department of Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences (AIIMS), New Delhi, India

A R T I C L E   I N F O

Article history:
Received 3 September 2020
Received in revised form 7 November 2020
Accepted 19 March 2021

Keywords:
COVID-19
Non-invasive ventilation (NIV)
Subcutaneous emphysema

A B S T R A C T

A patient with coronavirus disease-2019 (COVID-19) developed bilateral subcutaneous emphysema involving the neck and upper chest following the institution of non-invasive ventilation (NIV) for worsening hypoxia. We discuss the various causes, differentials and successful management of this patient.

© 2021 Elsevier Ltd. All rights reserved.

1. Introduction

The COVID-19 pandemic, has seen an increase in the number of patients suffering from varying degrees of breathing difficulties requiring oxygen (O2) supplementation via face mask, non-rebreathing/reservoir face mask (NRBM), high flow nasal cannula (HFNC), NIV support or invasive ventilation. These patients are considered “happy hypoxics” and intubated only when there are clinical signs of increased work of breathing, desaturation, evolving hypercapnia, worsening mental status, hemodynamic instability or multiorgan failure. Currently, the use of HFNC or NIV is reserved for mild hypoxemia, with airborne precautions [1]. Common complications associated with NIV are pressure ulcers/necrosis of nasal bridge, facial or ocular abrasions, oronasal mucosal dryness, claustrophobia, anxiety, agitation, aerophagia, abdominal distension, vomiting, aspiration, hemodynamic instability, impaired communication and impaired nutrition. Rare complications are barotrauma, pneumothorax, pneumomediastinum, pneumocephaalus, raised intracranial pressure and raised intraocular pressure. Cases of NIV induced pneumomediastinum and subcutaneous emphysema (SE) have been reported in patients with chronic obstructive pulmonary disease (COPD) and asthma [2]. Recently a few authors have also reported this in Covid-19 patients [3,4]. In this communication we report an occurrence of bilateral subcutaneous emphysema in a patient of COVID-19 pneumonia without pneumothorax and pneumomediastinum having no previous history of respiratory disease.

2. Case report

A 34 year male patient presented with the complains of fever and cough for 6 days and shortness of breath for 1 day duration. He was a known case of type 2 diabetes mellitus since 5 years, well controlled on oral anti-diabetic agents. Other medical and surgical history was unremarkable. On examination, patient was conscious and oriented with heart rate (HR)- 110/min, blood pressure (BP)- 115/91 mm Hg, oxygen saturation (SpO2)- 92% on room air and respiratory rate (RR)- 22/min. As he tested positive for SARS COV-2 he was shifted to the COVID-19 care isolation ward and was started on supportive treatment as per our institutional protocol. O2 was supplemented initially via a face mask and later via a NRBM and he was advised awake proning. His chest x-ray showed bilateral lower lobe infiltrates (Fig. 1a). On the next day of admission he became tachypnoeic (RR 30–34/min), SpO2- 88%, Arterial blood gas (ABG) showed mild hypoxemia, not improving with NRBM. The patient was put on NIV with inspiratory positive airway pressure 12 cmH2O, expiratory positive airway pressure 8 cmH2O and a fraction of inspired oxygen (FiO2) 0.6. After a day of NIV he complained of pain and swelling in the neck. On examination, his neck appeared uniformly swollen and crepitus was palpable in the bilateral supraclavicular fossa extending on to both sides of the neck and upper chest. A bed-side chest ultrasonography was negative for pneumothorax. An x-ray of the chest and neck showed increased...
lucency along subcutaneous tissue of neck bilaterally diagnostic of subcutaneous emphysema without pneumothorax (Fig. 1b). He was hemodynamically stable with SpO2 97% and normal blood gases and hence planned for conservative management. O2 was provided via NRBM under continuous monitoring for respiratory parameters and emphysema progression. HFNC was kept on standby as a rescue measure if the patient deteriorated further. HFNC provides improved oxygenation, decreased anatomical dead space, decreased metabolic demand of breathing, decreased production of carbon dioxide, superior comfort, improved work of breathing, better compliance, positive nasopharyngeal and tracheal airway pressure, better secretion clearance and has lesser risk of barotrauma. The patient remained stable with NRBM and maintained SpO2 above 95%. Subcutaneous emphysema was clinically non progressive and started showing gradual resolution on subsequent serial chest x-rays (Fig. 1b–d). O2 requirement gradually decreased and he started maintaining saturation above 96% on room air and crepitations resolved. The patient was discharged home in a stable condition on the 15th day post admission when he became negative for SARS COV-2.

3. Discussion

There has been an increase in the number of cases of SARS COV-2 and patients presenting with ARDS requiring ventilatory support. In early mild cases NIV has been advocated [5,6]. NIV is easy to apply, the patient can be self prone [7] and can also be used in the wards. Our patient developed subcutaneous emphysema after he was put on NIV. NIV induced barotrauma though rare, may present with pneumothorax, pneumomediastinum with subcutaneous emphysema. Spontaneous SE and pneumomediastinum has been reported due to a sudden rise in intra alveolar pressure resulting in imbalance in capillary and lung pressure and rupture of marginal alveoli and subsequent tracking of air along bronchi, interstitial and vascular support tissues into the mediastinum (Macklin effect) and then dissects through the soft tissue planes of the neck, producing the subcutaneous emphysema [8,9]. End expiratory pressure provided by NIV increases the pressure gradient between alveoli and the interstitial space and may cause alveolar rupture.

Pneumothorax with NIV has previously been reported in patients having neuro-muscular disease with pleural blebs, cystic fibrosis, asthma and previous history of trauma [10–12]. Pneumomediastinum is likely to be related to rapidly increased intrathoracic pressure due to coughing during NIV, increasing air trapping areas (emphysema) with alveolar septa rupture and enhancing traction on stiffness of small airways (peribronchial fibrosis) causing the discontinuation of bronchoalveolar junction [13]. Gonzalez and colleagues (2016) reported a case of NIV induced exacerbation of air leak resulting in intense cervical subcutaneous emphysema and pneumomediastinum in a patient with asthma [2]. SE can occur without pneumothorax or pneumomediastinum in patients with cavitary pulmonary tuberculosis [14]. Singh and colleagues reported a case of spontaneous SE and pneumomediastinum in a patient with H1N1 pneumonia [15]. COVID-19 pneumonia has been shown to cause severe diffuse alveolar damage (DAD) secondary to direct infection of pneumocytes type I and II. Studies have demonstrated COVID-19 viral entry via angiotensin converting enzyme-2 (ACE-2) receptor into target cells including surfactant-producing type II pneumocytes causing cellular injury and dysregulation of surfactant production contributing to the development of SE and pneumomediastinum from impaired lung compliance [16,17]. SE can be due to trauma, surgery, infections or spontaneous origin. SE has also been reported due to dental procedures, drug abuse, adenoid-tonsillctomies, bowel perforation, arthroscopy, strangulation of the neck from hanging. No precipitating risk factor was found in our patient. NIV was the most likely contributory factor as supported by serial chest x-ray findings (Fig. 1a–d). However, the probability of spontaneous bullae rupture cannot be denied. CT thorax would have thrown more light into the etiopathogenesis, but it was not performed due to logistical issues and also because the patient improved with conservative treatment measures. The possibility of pneumothorax was ruled out with bedside ultrasonography which showed normally sliding pleura over all of the chest quadrants and absent barcode or stratosphere sign on M-mode scan. Ultrasound has a sensitivity of 58.9%–95.3% and a specificity of 91.1%–99.6% for detecting pneumothorax [18].
4. Conclusion

An increased number of COVID-19 patients receive NIV for the management of acute hypoxemic respiratory failure. Subcutaneous emphysema, though rare may occur in these patients. Timely recognition, intervention and monitoring may help reduce progression to dangerous complications.

Author’s contribution

1. Dr Sunil Routaray, MD - Substantial contributions to conception and design and drafting of the article.
2. Dr Chandrakant Prasad, MD - Drafting of the article and critical revision for important intellectual content.
3. Dr Vanitha Rajagopalan, MD, DM - Drafting of the article and critical revision for important intellectual content.

Final approval of the version to be published.

Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved.

Declaration of competing interest

The authors have no conflict of interest to declare.

References

[1] J. Phua, L. Weng, L. Ling, M. Egi, C.M. Lim, J.V. Divatia, et al., Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations, Lancet Respir Med 2500 (2020) 30161–30162.
[2] G.L. González, C. Rey, A. Medina, C.J. Mayordomo, Severe subcutaneous emphysema and pneumomediastinum secondary to non-invasive ventilation support in status asthmaticus, Indian J. Crit. Care Med. 20 (2016) 242–244.
[3] B.A. Uçpinar, C. Sahin, U. Yanc, Spontaneous pneumothorax and subcutaneous emphysema in COVID-19 patient: case report, J. Infect. Public Health 13 (2020) 887–889.
[4] S. Manna, S.Z. Maron, M.A. Cedillo, Spontaneous subcutaneous emphysema and pneumomediastinum in non-intubated patients with COVID-19, Clin. Imag. 67 (2020) 207–213.
[5] B.K. Patel, J.P. Kress, J.B. Hall, Alternatives to invasive ventilation in the COVID-19 pandemic, J. Am. Med. Assoc. 9611 (2020) e1–e2.
[6] L. Ding, L. Wang, W. Ma, H. He, Efficacy and safety of early prone positioning combined with HFNC or NIV in moderate to severe ARDS: a multi-center prospective cohort study, Crit. Care 24 (2020) 28, 28.
[7] C. Sartini, M. Tresoldi, P. Scarpellini, A. Fettamani, F. Carco, G. Landoni, et al., Respiratory parameters in patients with COVID-19 after using non-invasive ventilation in the prone position outside the intensive care unit, Jama 7861 (2020) e1–e2.
[8] C.C. Macklin, Transport of air along sheaths of pulmonic blood vessels from alveoli to mediastinum: clinical implications, Arch. Intern. Med. 64 (1939) 913–926.
[9] R.J. Mauder, D.J. Pierson, L.D. Hudson, Subcutaneous and mediastinal emphysema. Pathophysiology, diagnosis, and management, Arch. Intern. Med. 148 (1984) 1447–1453.
[10] A.K. Simonds, Pneumothorax: an important complication of non-invasive ventilation in neuromuscular disease, Neuromusc. Disord. 14 (2004) 351–352.
[11] C.S. Haworth, M.E. Dodd, M. Atkins, A.A. Woodcock, A.K. Webb, Pneumothorax in adults with cystic fibrosis dependent on nasal intermittent positive pressure ventilation (NIPPV): a management dilemma, Thorax 55 (2000) 620–622.
[12] A.R. Medford, J.C.T. Pepperell, Pneumothorax following non-invasive ventilation for acute asthma, J. R. Coll. Phys. Edinb. 36 (2006) 29–31.
[13] P. Ruggert, G. Girbino, Fatal pneumomediastinum associated with use of noninvasive mechanical ventilation, Respirol. Case Rep. 2 (2014) 126–128.
[14] R. Dixit, J. George, Subcutaneous emphysema in cavitary pulmonary tuberculosis without pneumothorax or pneumomediastinum, Lung India 29 (2012) 70–72.
[15] B.P. Singh, G.S. Shetty, P.A. Vijayan, U. Gopalakrishna, G. Chandan, A. Santini, et al., Management of pneumomediastinum associated with H1N1 pneumonia: a case report, J. Crit. Care Med. 5 (2019) 28–33.
[16] M. Hoffmann, H. Kleine-Weber, S. Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2020) 271–280.
[17] S. Kolani, N. Houari, M. Haloua, Spontaneous pneumomediastinum occurring in the SARS-COV-2 infection 21 (2020), e00806. ID Cases.
[18] L.F. Husain, L. Hagopian, D. Wayman, W.E. Baker, K.A. Carmody, Sonographic diagnosis of pneumothorax, J. Emergencies, Trauma, Shock 5 (2012) 76–81.